JOURNAL DESCRIPTION
The Medical Radiology and Radiation Safety journal ISSN 1024-6177 was founded in January 1956 (before December 30, 1993 it was entitled Medical Radiology, ISSN 0025-8334). In 2018, the journal received Online ISSN: 2618-9615 and was registered as an electronic online publication in Roskomnadzor on March 29, 2018. It publishes original research articles which cover questions of radiobiology, radiation medicine, radiation safety, radiation therapy, nuclear medicine and scientific reviews. In general the journal has more than 30 headings and it is of interest for specialists working in thefields of medicine¸ radiation biology, epidemiology, medical physics and technology. Since July 01, 2008 the journal has been published by State Research Center - Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. The founder from 1956 to the present time is the Ministry of Health of the Russian Federation, and from 2008 to the present time is the Federal Medical Biological Agency.
Members of the editorial board are scientists specializing in the field of radiation biology and medicine, radiation protection, radiation epidemiology, radiation oncology, radiation diagnostics and therapy, nuclear medicine and medical physics. The editorial board consists of academicians (members of the Russian Academy of Science (RAS)), the full member of Academy of Medical Sciences of the Republic of Armenia, corresponding members of the RAS, Doctors of Medicine, professor, candidates and doctors of biological, physical mathematics and engineering sciences. The editorial board is constantly replenished by experts who work in the CIS and foreign countries.
Six issues of the journal are published per year, the volume is 13.5 conventional printed sheets, 88 printer’s sheets, 1.000 copies. The journal has an identical full-text electronic version, which, simultaneously with the printed version and color drawings, is posted on the sites of the Scientific Electronic Library (SEL) and the journal's website. The journal is distributed through the Rospechat Agency under the contract № 7407 of June 16, 2006, through individual buyers and commercial structures. The publication of articles is free.
The journal is included in the List of Russian Reviewed Scientific Journals of the Higher Attestation Commission. Since 2008 the journal has been available on the Internet and indexed in the RISC database which is placed on Web of Science. Since February 2nd, 2018, the journal "Medical Radiology and Radiation Safety" has been indexed in the SCOPUS abstract and citation database.
Brief electronic versions of the Journal have been publicly available since 2005 on the website of the Medical Radiology and Radiation Safety Journal: http://www.medradiol.ru. Since 2011, all issues of the journal as a whole are publicly available, and since 2016 - full-text versions of scientific articles. Since 2005, subscribers can purchase full versions of other articles of any issue only through the National Electronic Library. The editor of the Medical Radiology and Radiation Safety Journal in accordance with the National Electronic Library agreement has been providing the Library with all its production since 2005 until now.
The main working language of the journal is Russian, an additional language is English, which is used to write titles of articles, information about authors, annotations, key words, a list of literature.
Since 2017 the journal Medical Radiology and Radiation Safety has switched to digital identification of publications, assigning to each article the identifier of the digital object (DOI), which greatly accelerated the search for the location of the article on the Internet. In future it is planned to publish the English-language version of the journal Medical Radiology and Radiation Safety for its development. In order to obtain information about the publication activity of the journal in March 2015, a counter of readers' references to the materials posted on the site from 2005 to the present which is placed on the journal's website. During 2015 - 2016 years on average there were no more than 100-170 handlings per day. Publication of a number of articles, as well as electronic versions of profile monographs and collections in the public domain, dramatically increased the number of handlings to the journal's website to 500 - 800 per day, and the total number of visits to the site at the end of 2017 was more than 230.000.
The two-year impact factor of RISC, according to data for 2017, was 0.439, taking into account citation from all sources - 0.570, and the five-year impact factor of RISC - 0.352.
Medical Radiology and Radiation Safety. 2017. Vol. 62. No. 2. P. 79-82
DOI: 10.12737/article_58f0b95756aed8.04575649
Case of Inflammatory Myofibroblastic Tumor of Mesentery with Significant Fatty Component
A.N. Bashkov1, Z.V. Sheykh2, S.V. Cholakyan1, E.A. Ionova1, V.I. Doga1, М.А. Shabalin1, O.O. Grigor’eva1
1. A.I. Burnasyan Federal Medical Biophysical Center of FMBA, Moscow, Russia, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; 2. S.P. Botkin City clinical hospital Moscow, Russia
Bаshkov A.N. - Head of Radiology Department; Sheykh Z.V. - Dr. Sci. Med., Professor, Head of Radiology Department; Cholakyan S.V. - Surgeon; Ionova E.A. - Dr. Sci. Med.; Doga V.I. - Head of Rentgenology Department; Shabalin M.A. - Surgeon; Grigor’eva O.O. - Radiologist
Abstract
Purpose: To describe own observation of inflammatory myofibroblastic tumor (IMT) of mesentery with a significant fatty component, retrospectively evaluate the diagnostic capabilities of computed tomography (CT).
Material and methods: CT with bolus intravenous administration of 100 ml of contrast agent Ultravist-370 was performed by multislice computed tomograph Aquilion 64 Toshiba.
Results: Patient M., 55 years old, was admitted to the clinic in July 2016 for surgical treatment due to the tumor in the abdominal cavity, which was detected by CT in May 2016. From the history it is known that since January 2016 the patient began to complain of weakness and weight loss. There were no abnormalities during physical examination and in the laboratory data. For staging pathological process control CT of the abdominal cavity with intravenous contrast was performed and then compared with previous СT scan. On the images of CT examination in the May 2016 in the mesogaster to the right of the median line oval shaped mass was defined, its seizes were 51x55x58 mm. On the present images seizes have reduced by about 10mm, more significantly decreased the volume of the mass - from 87 ml to 54 ml. The tumor is located directly under the anterior abdominal wall, surrounded by a loop of the small intestine. The outlines of mass were clear and smooth. The structure was not uniform due to inclusions of areas of fat (-75 HU) ranging in size from 4 mm to 29?16 mm, soft tissue component demonstrated the accumulation of contrast agent from 35 HU in the native phase to a maximum of 74 HU in delayed phase. There were not any other changes in the abdomen.
So after 2 months at the control CT scan before the planned surgery we observed positive changes in the form of reducing the size and more significantly volume of the lesion. In the differential range we considered fat-containing tumors - teratoma and liposarcoma. We did not think about inflammatory myofibroblastic tumor (IMT) as well as gastrointestinal stromal tumor, since the guidelines for X-ray diagnostics and different overviews of these tumors does not mention the possibility of the presence of fat in their structure. However, there were not any pathognomonic features of teratoma like calcification, cystic component, levels of fat / liquid. The outline of the mass was smooth and clear, so we could suggest an expansive rather than infiltrative growth, which has also made the conclusion about liposarcoma unlikely.
After preoperative preparation surgery was performed in the amount of resection of the small intestine segment with tumor and making enteroenteroanastomosis «end to end». After the morphological and immunohistochemistry analysis IMT of mesentery of small intestine was diagnosed.
Conclusion: 1. Fatty component in the structure of lesion of the mesentery of the small intestine does not rule out IMT. 2. Theoretically we can assume the possible presence of fat in the structure of the IMT any location. 3. Consideration should be given by IMT in the case of spontaneous reduction of the size of the observed tumor.
Key words: inflammatory myofibroblastic tumor, mesentery, fatty component, computed tomography
REFERENCES
- Lakshmana Das Narla et al. Inflammatory pseudotumor. Radio. Graphics. 2003. Vol. 23. P. 719-729.
- Stepanova Yu.A., Karmazanovskij G.G., Shchegolev A.I. et al. Vospalitel’naya miofibroblasticheskaya opuhol’ pecheni: obzor literatury i klinicheskoe nablyudenie. Med. vizualizaciya. 2011. No. 2. P. 34-46.
- Groenveld R.L., Raber M.H., Oosterhof-Berktas R., Eijken E. Abdominal inflammatory myofibroblastic tumor. Case Rep. Gastroenterol. 2014. Vol. 8. P. 67-71.
- Chaudhary P. Mesenteric inflammatory myofibroblastic tumors. Ann. Gastroenterol. 2015. Vol. 28. P. 49-54.
- Madhavi P., Sevrukov A.B., Elsayes R.M. et al. Inflammatory pseudotumor: the great mimicker. Amer. J. Roentgenol. 2012. Vol. 198. No. 3. P. 217-227.
- Leavy A.D. Benign fibrous tumors and tumorlike lesions of the mesentery: radiologic-pathologic correlation. RadioGraphics. 2006. Vol. 26. P. 245-264.
- Coffin C.M., Hornick J.L., Fletcher C.D. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Amer. J. Surg. Pathol. 2007. Vol. 31. P. 509-520.
- Liang H.H., Chai C.Y., Lin Y.H. et al. Jejunal and multiple mesenteric calcifying fibrous pseudotumor induced jejunojejunal intussusception. J. Formos. Med. Assoc. 2007. Vol. 106. P. 485-489.
- Kutluk T., Emir S., Karnak I., Gaglar M. Mesenteric inflammatory pseudotumor: unusual presentation with leukemoid reaction and massive calcified mass. J. Pediatr. Hematol. Oncol. 2002. Vol. 24. P. 158-159.
- Hirose Y., Kaida H., Kurata S. et al. Incidental detection of rare mesenteric inflammatory pseudotumor by (18)F-FDG PET. Hell. J. Nucl. Med. 2012. Vol. 15. P. 247-250.
- Murga-Zamalloa C., Lim M.S. ALK-driven tumors and targeted therapy: focus on crizotinib. Pharmgenomics Pers. Med. 2014. Vol. 7. P. 87-94.
- Mossé Y.P., Balis F.M., Lim M.S. et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a children’s oncology group phase I consortium study. J. Clin. Oncol. 2012. Vol. 30. P. 15-20.
For citation: Bashkov AN, Sheykh ZV, Cholakyan SV, Ionova EA, Doga VI, Shabalin МА, Grigoreva OO. Case of Inflammatory Myofibroblastic Tumor of Mesentery with Significant Fatty Component. Medical Radiology and Radiation Safety. 2017;62(2):79-82. Russian. DOI: 10.12737/article_58f0b9572d7131.31568909
PDF (RUS) Full-text article (in Russian)